An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
1 Online-Ressource.
- Sprache
-
Englisch
- Erschienen in
-
An alternative fully human anti-BCMA CAR-T shows response for relapsed or refractory multiple myeloma with anti-BCMA CAR-T exposures previously ; volume:31 ; number:3 ; day:15 ; month:12 ; year:2023 ; pages:420-426 ; date:3.2024
Cancer gene therapy ; 31, Heft 3 (15.12.2023), 420-426, 3.2024
- Urheber
-
Wang, Qingming
Wei, Runhong
Guo, Shufang
Min, Chao
Zhong, Xiong
Huang, Hui
Cheng, Zhi
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41417-023-00712-0
- URN
-
urn:nbn:de:101:1-2405061040463.591916998437
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wang, Qingming
- Wei, Runhong
- Guo, Shufang
- Min, Chao
- Zhong, Xiong
- Huang, Hui
- Cheng, Zhi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Engineering CAR-T cells
CAR-T-derived extracellular vesicles: a promising development of CAR-T anti-tumor therapy
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Strategies to enhance CAR-T persistence
Gut microbiome and CAR-T therapy
Target selection for CAR-T therapy
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies
Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
Recent advances in CAR-T cell engineering
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Engineering CAR-T cells
CAR-T-derived extracellular vesicles: a promising development of CAR-T anti-tumor therapy
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Strategies to enhance CAR-T persistence
Gut microbiome and CAR-T therapy
Target selection for CAR-T therapy
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies
Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma
Recent advances in CAR-T cell engineering
Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy
Engineering CAR-T cells
CAR-T-derived extracellular vesicles: a promising development of CAR-T anti-tumor therapy
Cost of implementing CAR-T activity and managing CAR-T patients: an exploratory study
Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond
Strategies to enhance CAR-T persistence
Gut microbiome and CAR-T therapy
Target selection for CAR-T therapy
Superior anti-tumor efficacy of CD4⁺ CAR-T cells in hematological malignancies
Interleukin-7 expression by CAR-T cells improves CAR-T cell survival and efficacy in chordoma
Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma